| アブストラクト | Chimeric antigen receptor T-cell (CAR-T) therapy has shown remarkable efficacy in treating relapsed/refractory B-cell malignancies, as supported by real-world evidence (RWE). However, limited RWE exists on the management of adverse events during the perioperative period following CAR-T infusion. This study was conducted to obtain RWE on perioperative management using the Japanese Diagnosis Procedure Combination database, a comprehensive repository of Japanese health and medical service data. Between November 2019 and March 2022, 388 patients received CAR-T therapy. Of these, 312 had large B-cell lymphoma (LBCL) and 76 had B-cell acute lymphoblastic leukemia (B-ALL). The number of CAR-T infusions increased every 6-month interval, correlating with the rise in LBCL cases. Tocilizumab was administered for cytokine release syndrome in 56.1% of LBCL and 42.1% of B-ALL patients. Steroids were used for 22.9% and 81.3%, respectively. Prophylaxis for fungal infections was administered during CAR-T infusion in most LBCL and B-ALL patients. Treatment intensity was escalated in 2.8% of LBCL and 7.0% of B-ALL patients, and treatment for cytomegalovirus infection was initiated in approximately 7% of patients. This analysis elucidated perioperative management strategies based on patients' medication histories. |
|---|
| ジャーナル名 | International journal of hematology |
|---|
| Pubmed追加日 | 2025/8/7 |
|---|
| 投稿者 | Tanaka, Keisuke; Kikuchi, Hiroaki; Umezawa, Yoshihiro; Mori, Takehiko; Fushimi, Kiyohide; Yamamoto, Masahide |
|---|
| 組織名 | Department of Hematology, Institute of Science Tokyo Hospital, 1-5-45 Yushima,;Bunkyo-ku, Tokyo, 113-8510, Japan.;Department of Nephrology, Graduate School of Medical and Dental Sciences,;Institute of Science Tokyo, Tokyo, Japan.;Department of Health Policy and Informatics, Graduate School of Medical and;Dental Sciences, Institute of Science Tokyo, Tokyo, Japan.;Bunkyo-ku, Tokyo, 113-8510, Japan. hide.hema@tmd.ac.jp. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40770123/ |
|---|
